NCT06856343 REBECCA Real-world Early BrEast CanCer mAnagement
| NCT ID | NCT06856343 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 126 participants |
| Start Date | 2024-12-30 |
| Primary Completion | 2028-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 126 participants in total. It began in 2024-12-30 with a primary completion date of 2028-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.
Eligibility Criteria
Inclusion Criteria: * Male or female aged ≥ 18 years * Patient diagnosed with HER2-negative eBC * Patient about to be initiated with adjuvant Olaparib at their physician's discretion * Patient has been informed and does not object to participation in the study. Exclusion Criteria: * Patient not consenting to participate. * Patients included in the Early Access Program
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06856343 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06856343 currently recruiting?
Yes, NCT06856343 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT06856343 trial being conducted?
This trial is being conducted at Clermont-Ferrand, France, Gleizé, France, Grenoble, France, Lyon, France and 11 additional locations.
Who is sponsoring the NCT06856343 clinical trial?
NCT06856343 is sponsored by AstraZeneca. The trial plans to enroll 126 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.